All In Biotech

Drug Trial Radar · NCT04108195

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

290

Actual

Start

Feb 21, 2020

Primary completion

Apr 7, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.

Conditions

  • Multiple Myeloma

Interventions

  • DaratumumabDrug

    Participants will receive daratumumab.

  • TalquetamabDrug

    Participants will receive talquetamab.

  • TeclistamabDrug

    Participants will receive teclistamab.

  • PomalidomideDrug

    Participants will receive pomalidomide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 52 Weeks
  2. Part 1: Number of Participants With Dose Limiting Toxicity by SeverityTime frame: Up to 52 Weeks
  3. Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 48 Weeks
  4. Part 2: Number of Participants With Adverse Events and SAEs by SeverityTime frame: Up to 48 Weeks

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California

  • University of California San Francisco

    San Francisco, California

  • The Blavatnik Family Chelsea Medical Center at Mount Sinai

    New York, New York

  • Mount Sinai Medical Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin

  • Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • University Health Network UHN Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Universitatsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany

  • Universitatsklinikum Wurzburg

    Würzburg, Germany

  • VU Medisch Centrum

    Amsterdam, Netherlands

  • LUMC

    Leiden, Netherlands

  • Hosp Clinic de Barcelona

    Barcelona, Spain

  • Inst. Cat. Doncologia-H Duran I Reynals

    Barcelona, Spain

  • Germans Trias I Pujol

    Barcelona, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain

  • Clinica Univ. de Navarra

    Pamplona, Spain

  • Hosp Clinico Univ de Salamanca

    Salamanca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.